TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Plummer R. et al, (2025), Cell rep med
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane database syst rev, 3
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.
Chettle J. et al, (2024), Hgg adv, 5
Access divergence to new cancer medicines in the United Kingdom.
Lythgoe MP. et al, (2024), Eur j cancer, 207
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J exp clin cancer res, 43
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Janku F. et al, (2024), Cancers, 16
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
Dixon-Zegeye M. et al, (2024), Trials, 25
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.
Lythgoe MP. et al, (2023), Lancet oncol, 24, 963 - 966
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), Bmj support palliat care
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Luke JJ. et al, (2023), Br j cancer
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R. et al, (2023), British journal of cancer
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
Lythgoe MP. et al, (2023), The lancet oncology, 24, e150 - e160